Id: acc0640
Group: 1sens
Protein: NT5C2
Gene Symbol: NT5C2
Protein Id: P49902
Protein Name: 5NTC_HUMAN
PTM: phosphorylation
Site: Ser502
Site Sequence: THVDINEMESPLATRNRTSVD
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: ALL
Disease Cellline: Jurkat
Disease Info:
Drug: 6-MP
Drug Info: "6-MP (6-Mercaptopurine) is a chemotherapeutic agent and purine analog that competitively inhibits hypoxanthine conversion, thereby suppressing DNA and RNA synthesis, primarily used in the treatment of acute leukemias (especially childhood acute lymphoblastic leukemia), choriocarcinoma, and malignant hydatidiform mole."
Effect: inhibit
Effect Info: Phosphorylation of NT5C2 at Ser502 induces NT5C2 activation and drives tumor cell resistance to 6 - MP at relapse.
Note:
Score: 5.0
Pubmed(PMID): 35984649
Sentence Index:
Sentence:

Sequence & Structure:

MSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNLFPLAPQEITHCHDEDDDEEEEEEEE

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

NT5C2-Ser511
Cancer Intensity
BRCA
COAD -0.261
HGSC 1.378
ccRCC
GBM -0.105
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -1.011
NT5C2-Thr510
Cancer Intensity
BRCA
COAD -0.491
HGSC 1.151
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.659

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 502 U Acute lymphocytic leukemia Phosphorylation 35984649

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: